MNPR peer analysis
Monopar Therapeutics (MNPR) against its competitors: price, today's move, 1-year return and market value side by side.
MNPR and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ADCT ADC Therapeutics | $1.53 | 2.68% | -66.95% | $195.33M |
| ALXO ALX Oncology | $1.22 | 0.00% | -21.29% | – |
| ATNM Actinium Pharmaceuticals | $1.48 | -3.27% | 4.23% | $46.53M |
| BCYC Bicycle Therapeutics | $3.66 | -4.19% | -58.22% | $256.54M |
| CMPX Compass Therapeutics | $0.79 | 4.01% | -78.86% | – |
| IMNM Immunome | $19.44 | 6.75% | 21.65% | – |
| IPHA Innate Pharma | $1.46 | -1.35% | -33.64% | $163.08M |
| MGNX MacroGenics | $2.40 | 0.84% | 50.47% | $152.88M |
| XNCR Xencor | $29.75 | -0.23% | 110.54% | $2.22B |
| ZYME Zymeworks | $28.57 | -0.14% | 49.42% | $2.02B |
| MNPR Monopar Therapeutics | $70.32 | -2.21% | -17.92% | $472.00M |
- MNPR's peers: ADCT (ADC Therapeutics), ALXO (ALX Oncology), ATNM (Actinium Pharmaceuticals), BCYC (Bicycle Therapeutics), CMPX (Compass Therapeutics), IMNM (Immunome), IPHA (Innate Pharma), MGNX (MacroGenics).
Updated 2026-11-02 17:54 UTC